UCSF home page | About UCSF | UCSF Medical Center

Skip to TransPortal content

Enlarge Text
Click to increase the text size. Restore Text
Click to restore original text size. Reduce Text
Click to decrease the text size.


Decrease the text size \| Restore text size \| Increase the text size

Cephaloridine

In Vitro Substrates

* denotes drugs that can potentially be used for in vivo (clinical) studies of the designated transporter

Transporter	Synonyms	Km (μM)	Cell System	Reference
SLC22A5	OCTN2	3000	hOCTN2-expressing oocytes	Kano, 2009

* denotes drugs that can potentially be used for in vivo (clinical) studies of the designated transporter

Transporter	Synonyms	Inhibitor	IC50 (μM)	Ki (μM)	Substrate used	Cell System	Reference
SLC22A6	OAT1	Cephaloridine	1250		6-carboxyfluorescein	CHO-OAT1	Cihlar, 2000
SLC22A8	OAT3	Cephaloridine	626.4		Estrone sulfate	HEK293 cells	Ueo, 2005
SLC22A5	OCTN2	Cephaloridine	180		L-carnitine	JAR-hOCTN2	Ganapathy, 2000
SLC22A5	OCTN2	Cephaloridine	230		L-carnitine	HeLa-OCTN2	Ganapathy, 2000
SLC22A5	OCTN2	Cephaloridine		379	L-carnitine	MDCKII-hOCTN2	Diao, 2010
SLC22A6	OAT1	Cephaloridine	2470		Para-aminohippurate	HEK293 cells	Ueo, 2005
SLC22A11	OAT4	Cephaloridine		3630	Prostaglandin F2-alpha	S2-OAT4	Khamdang, 2003
SLC22A6	OAT1	Cephaloridine		740	Prostaglandin F2-alpha	S2-OAT1	Khamdang, 2003
SLC22A7	OAT2	Cephaloridine	4480		Prostaglandin F2-alpha	S2-OAT2	Khamdang, 2003
SLC22A8	OAT3	Cephaloridine		2460	Prostaglandin F2-alpha	S2-OAT3	Khamdang, 2003

No drug-drug interaction information.